细胞减灭术联合腹腔热灌注化疗在结直肠癌腹膜转移治疗中的应用与展望
结直肠癌腹膜转移早期诊断困难、预后不良,既往以全身静脉化疗为主但不良反应明显且不能有效控制肿瘤进展。本文分析总结细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)治疗结直肠癌腹膜转移的生存疗效、预后因素及化疗安全性,并探讨HIPEC现存问题与争议。CRS+HIPEC已被国内外作为结直肠癌腹膜转移的一线治疗方案。
要点
- 腹膜为结直肠癌第2常见转移部位,早期诊断困难且预后不良。
- CRS+HIPEC可清除腹腔游离癌细胞与亚临床病灶并减轻全身不良反应。
- CRS+HIPEC已被国内外作为结直肠癌腹膜转移的一线治疗方案。
核心结论
- CRS+HIPEC可在有效清除腹腔内游离癌细胞与亚临床病灶的同时减轻化疗药物全身不良反应,最大程度实现宏观与微观的肿瘤根治。
- CRS+HIPEC目前已被国内外作为结直肠癌腹膜转移的一线治疗方案。
研究设计与样本
- 本文为针对CRS+HIPEC治疗结直肠癌腹膜转移的生存疗效、预后因素分析与化疗安全性进行聚焦分析与总结的综述,并同时探讨HIPEC治疗现存问题与争议。
主要发现
- 腹膜为结直肠癌第2常见转移部位,早期诊断困难且预后不良。
- 既往以全身性系统静脉化疗为主要治疗策略,其全身不良反应明显且不能有效控制肿瘤进展。
- 近年来外科技术、理念、设备的不断发展及新的化疗药物与靶向药物的出现,改善了结直肠癌腹膜转移患者的生存质量及预后。
临床怎么用
- CRS+HIPEC已被国内外作为结直肠癌腹膜转移的一线治疗方案。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Colorectal cancer is one of the common malignant tumors in China, and its incidence is increasing with years. As the second most common metastatic site of colorectal cancer, peritoneum is difficult to diagnose early and with a poor prognosis. Systemic intravenous chemotherapy was used as the main treatment strategy for peritoneal metastasis in the past, but its systemic toxic and side effects were obvious, and it could not effectively control tumor progression. In recent years, the continuous development of surgical techniques, concepts, and equipment, as well as the introduction of new chemotherapy drugs and targeted drugs have significantly improved the quality of life and prognosis of patients with peritoneal metastasis of colorectal cancer. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) can effectively eradicated the intraperitoneal free cancer cells and subclinical lesions, while reducing systemic side effects of chemotherapy drugs, and achieve the radical cure of the tumor at the macro and micro levels to the greatest extent. It has been used as the first-line treatment program for peritoneal metastasis of colorectal cancer at home and abroad. This article focuses on the analysis and summary of the survival efficacy, prognostic factor analysis, and chemotherapy safety of CRS+ HIPEC in the treatment of colorectal cancer peritoneal metastasis. The existing problems and controversies of HIPEC therapy are discussed simultaneously. 结直肠癌为我国常见恶性肿瘤之一,其发病率逐年上升。腹膜为结直肠癌第2常见转移部位,早期诊断困难,预后不良。既往多采取全身性系统静脉化疗作为腹膜转移的主要治疗策略,其全身不良反应明显,且不能有效控制肿瘤进展。近年来,外科技术、理念、设备的不断发展以及新的化疗药物与靶向药物的出现改善了结直肠癌腹膜转移患者的生存质量及预后。细胞减灭术(CRS)联合腹腔热灌注化疗(HIPEC)可在有效清除腹腔内游离癌细胞与亚临床病灶的同时,减轻化疗药物带来的全身不良反应,最大程度上实现宏观与微观的肿瘤根治,目前,CRS+HIPEC已被国内外作为结直肠癌腹膜转移的一线治疗方案。文章分析总结了CRS+HIPEC治疗结直肠癌腹膜转移的生存疗效、预后因素分析、化疗安全性等问题,探讨了HIPEC治疗目前存在的问题与争议。.
引用
- Zhou SC, Pei W, Zhou HT, et al. [Application and prospect of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal metastasis from colorectal cancer]. Zhonghua Zhong Liu Za Zhi. 2022. PMID: 35073651. doi:10.3760/cma.j.cn112152-20200628-00603
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。